6-氯-2,3-二氨基甲苯 | 673487-36-0

• 物质功能分类: 有机原料 - 氨基化合物
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 6-氯-2,3-二氨基甲苯
• 英文名称: 6-chloro-2,3-diaminotoluene
• 英文别名: 4-chloro-3-methylbenzene-1,2-diamine
• CAS: 673487-36-0
• 化学式: C₇H₉ClN₂
• 分子量: 156.615
• InChiKey: MJASWYJHGMJHER-UHFFFAOYSA-N

物化性质

• 熔点：
  46-47 °C(Solv: benzene (71-43-2); ligroine (8032-32-4))
• 沸点：
  305.6±37.0 °C(Predicted)
• 密度：
  1.281±0.06 g/cm3(Predicted)
• pKa：
  3.65±0.10 (Predicted,Most Basic Temp: 25 °C)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  52
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 海关编码：
  2921590090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 6-Chloro-2,3-diaminotoluene
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 6-Chloro-2,3-diaminotoluene
CAS number: 673487-36-0

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C7H9ClN2
Molecular weight: 156.6

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

简介

6-氯-2,3-二氨基甲苯是一种白色固体粉末，在常温常压下具有显著的碱性和较强的亲核性，主要用作有机合成和医药化学中间体。由于其苯环上含有两个邻位的氨基单元，可与醛类物质发生缩合反应制备相应的苯并咪唑类衍生物，广泛应用于苯并咪唑类药物分子和生物活性分子的制备。例如，6-氯-2,3-二氨基甲苯可以用于合成药物分子萘莫雷生。

制备

将3-氯-2-甲基-6-硝基苯胺溶解于乙酸和水混合物中，并加热至90摄氏度。随后加入铁粉，继续在90摄氏度下反应2小时。反应结束后，冷却至室温并将混合物倒入冰水中，调整pH值至8后，再加入乙酸乙酯。过滤得到的混合物并分离有机相，用无水硫酸钠干燥有机层，过滤除去干燥剂并将所得滤液在真空条件下浓缩。最后，在硅胶上进行柱层析纯化，并用戊烷：乙酸乙酯洗脱，即可得到6-氯-2,3-二氨基甲苯。

反应信息

• 作为反应物：
  描述：

  6-氯-2,3-二氨基甲苯 在 盐酸 、 溶剂黄146 、 N,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 作用下， 以 甲醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 36.0h， 生成 ((2S,4S)-2-(6-chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-4-fluoropyrrolidin-1-yl)(5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone
  参考文献：
  名称：

  [EN] BENZIMIDAZOLE-PROLINE DERIVATIVES
  [FR] DÉRIVÉS DE BENZIMIDAZOLE-PROLINE

  摘要：

  本发明涉及式（I）的化合物，其中Ar1、R1、R2、R3、R4a、R4b和（R5）n如描述中所述，其制备方法，其药用盐以及作为药物的用途，含有一个或多个式（I）化合物的药用组合物，尤其是作为促进睡眠的药物受体拮抗剂的用途。

  公开号：

  WO2013182972A1
• 作为产物：
  描述：

  6-氯-2,3-二硝基甲苯 在 乙醇 、 水 、 铁粉 、 氯化铵 作用下， 反应 16.0h， 生成 6-氯-2,3-二氨基甲苯
  参考文献：
  名称：

  [EN] TETRAHYDROPYRROLOCYCLIC COMPOUND AND APPLICATION THEREOF
  [FR] COMPOSÉ TÉTRAHYDROPYRROLOCYCLIQUE ET SON APPLICATION
  [ZH] 四氢吡咯并环化合物及其应用

  摘要：

  一种式(I)所示的四氢吡咯并环化合物、其药学上可接受的盐及其在制备治疗选择性食欲素-2(OX-2)受体拮抗剂相关疾病的药物上的应用，相关疾病选自失眠、抑郁。

  公开号：

  WO2022166768A1
• 作为试剂：
  描述：

  6-氯-2,3-二氨基甲苯 、 N-BOC-2-甲基-L-脯氨酸 在 6-氯-2,3-二氨基甲苯 作用下， 生成 (S)-tert-butyl 2-((2-amino-4-chloro-3-methylphenyl)carbamoyl)-2-methylpyrrolidine-1-carboxylate
  参考文献：
  名称：

  Crystalline form of (S)-(2-(6-chloro-7-methyl-1H-benzo[D]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone and its use as orexin receptor antagonists

  摘要：

  本发明涉及(S)-(2-(6-氯-7-甲基-1H-苯并[d]咪唑-2-基)-2-甲基吡咯烷-1-基)(5-甲氧基-2-(1,2,3-三唑-2-基)苯基)甲酮的晶体形式，其制备方法，含有这种晶体形式的制药组合物，由这种晶体形式制备的制药组合物，以及它们作为药物的用途，特别是作为脑下垂体前叶皮质素受体拮抗剂。

  公开号：

  US09914720B2

文献信息

• [EN] USE OF BENZIMIDAZOLE-PROLINE DERIVATIVES<br/>[FR] UTILISATION DE DÉRIVÉS DE BENZIMIDAZOLE-PROLINE
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：WO2015083094A1

  公开（公告）日：2015-06-11

  The present invention relates to compounds of the formula (I), wherein Ar1 and Ar2 are as described in the description and to their use as pharmaceuticals for the treatment of sundown syndrome. The invention also relates to the preparation of such compounds and of pharmaceutically acceptable salts thereof.

  本发明涉及式(I)的化合物，其中Ar1和Ar2如描述中所述，并且它们作为治疗日落综合征的药物的用途，该发明还涉及制备这种化合物及其药用盐的方法。
• [EN] PYRAZOLOPYRAZINES ACTING ON CANCERS VIA INHIBITION OF CDK12<br/>[FR] PYRAZOLOPYRAZINES AGISSANT SUR DES CANCERS PAR INHIBITION DE CDK12
  申请人：BAYER AG

  公开号：WO2021176049A1

  公开（公告）日：2021-09-10

  The present invention provides compounds of general formula (I) in which X, R1, R2 and R3 are as described and defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions for the treatment and/or prophylaxis of diseases, in particular of hyperproliferative disorders such as cancer disorders, as a sole agent or in combination with other active ingredients.

  本发明提供了一般式(I)中X、R1、R2和R3如所述和定义的化合物，制备所述化合物的方法，用于制备所述化合物的中间化合物，包含所述化合物的药物组合物和组合物，以及利用所述化合物制造用于治疗和/或预防疾病的药物组合物，特别是治疗癌症等高增殖性疾病的药物组合物，作为唯一药剂或与其他活性成分结合使用。
• [EN] INHIBITORS OF TYPED 1 METHIONYL-TRNA SYNTHETASE AND METHODS OF USING THEM<br/>[FR] INHIBITEURS DE MÉTHIONYL-ARNT SYNTHÉTASE DE TYPE 1 ET LEURS MÉTHODES D'UTILISATION
  申请人：UNIV WASHINGTON

  公开号：WO2018237349A1

  公开（公告）日：2018-12-27

  The present disclosure is generally directed to compositions useful in the inhibition of MetRS and methods for treating diseases that are ameliorated by the inhibition of MetRS.

  本公开涉及的是通常用于抑制MetRS的组合物和治疗通过抑制MetRS改善的疾病的方法。
• [EN] 2-(2-AZABICYCLO[3.1.0]HEXAN-1-YL)-1H-BENZIMIDAZOLE DERIVATIVES<br/>[FR] DÉRIVÉS DE 2-(2-AZABICYCLO [3.1.0] HEXAN-1-YL)-1H-BENZIMIDAZOLE
  申请人：IDORSIA PHARMACEUTICALS LTD

  公开号：WO2020007964A1

  公开（公告）日：2020-01-09

  The present invention relates to compounds of the Formula (I) wherein Ar1, R1, and (R5)n are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of Formula (I), and especially to their use as orexin receptor antagonists.

  本发明涉及式（I）的化合物，其中Ar1，R1和（R5）n如描述中所述，以及它们的制备，其药学上可接受的盐，以及它们作为药物的用途，包括含有一种或多种式（I）化合物的药物组合物，特别是它们作为促进睡眠的奥莱欣受体拮抗剂的用途。
• Octahydropyrrolo[3,4-C]pyrrole derivatives
  申请人：Lane Alice Louise Charlotte

  公开号：US20060111416A1

  公开（公告）日：2006-05-25

  The present invention relates to octahydropyrrolo[3,4-c]pyrrole derivatives of formula (I): and to processes for the preparation thereof, compositions containing the same and the uses thereof.

  本发明涉及式(I)的八氢吡咯并[3,4-c]吡咯衍生物，以及其制备方法、含有该衍生物的组合物和用途。